TORONTO, April 12, 2024 (GLOBE NEWSWIRE) — The Ontario Psychological Association (OPA) today released a pivotal report, “Mental Health in Ontario: Insights from AskForHelpToday.ca,” based on an analysis of over 12,000 referrals since the platform’s inception in 2021. This comprehensive document offers an unprecedented look into the mental health demands and the evolving role of digital health in addressing these needs.
Key Findings:
Additionally, the report brings to light the concerning issue of high cancellation rates due to a lack of insurance coverage for mental health services. It underscores the pressing need for OHIP-type coverage to bridge this gap, ensuring that financial barriers do not prevent Ontarians from accessing the mental health care they need.
“The insights from the AskForHelpToday.ca report serve as a crucial call to action,” said Dr. Sylvain Roy, clinical lead at AskForHelpToday.ca. “They spotlight the increasing demand for mental health services and highlight the significant impact of digital health solutions in addressing these needs.”
The report is positioned as a resource for policymakers, healthcare providers, and stakeholders in the mental health sector, advocating for strategic, data-driven approaches to enhance service accessibility, address insurance gaps, and improve care quality. The full report is available here.
For more information please contact:
Richard Morrison
Chief Executive Officer
Ontario Psychological Association
Richard@psych.on.ca
About the Ontario Psychological Association
The Ontario Psychological Association is a not-for-profit organization and the professional association representing psychology in Ontario. OPA is steadfast in its commitment to advancing mental health care in Ontario through research, education, clinical excellence, and advocacy.
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…